President and Chief Operating Officer, Agenus
Advantages of Invariant Natural Killer T Cell Therapies
Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed the company’s iNKT cell platform.
Using Cell Therapies for Cancer and Beyond
Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed cell therapy for multiple myeloma and COVID-19 respiratory distress.
Developing Oncolytic Cell Therapies With VISION
Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed the VISION platform the company uses to develop therapies.
Targeting Relapsing/Refractory Multiple Myeloma With Cell Therapy
The president and chief operating officer of Agenus discussed the cell therapies the company is developing for the treatment of multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512